Substance / Medication

Nafarelin

Overview

Active Ingredient
nafarelin
RxNorm CUI
28656

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Dose of GnRH agonist (nafarelin acetate) affects intrafollicular PAPP-A expression in controlled ovarian hyperstimulation cycle.
Suh JiHyun, Lee EunYoung, Hwang SeongSoo et al. · Eur J Obstet Gynecol Reprod Biol · 2004
PMID: 14687742Observational
Delivery and stability of LHRH and Nafarelin in human skin: the effect of constant/pulsed iontophoresis.
Raiman Johanna, Koljonen Maija, Huikko Katri et al. · Eur J Pharm Sci · 2004
PMID: 14757511Observational
Acute exacerbation of chronic maxillary sinusitis during therapy with nafarelin nasal spray.
Heinig J, Coenen-Worch V, Cirkel U · Eur J Obstet Gynecol Reprod Biol · 2001
PMID: 11788185Case Report
Crohn's disease mimicking as bowel endometriosis. Are the symptoms reduced by nafarelin acetate?
Nakao A, Iwagaki H, Kanagawa T et al. · Arch Gynecol Obstet · 2000
PMID: 10763842Case Report
Prolonged injectable formulation of Nafarelin using in situ gel combination delivery system.
Alizadeh Behnoush, Bahari Javan Nika, Akbari Javar Hamid et al. · Pharm Dev Technol · 2018
PMID: 28430010Other
A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan.
Cheng Ming-Huei, Yu Bill Ken-Jen, Chang Sheng-Ping et al. · J Chin Med Assoc · 2005
PMID: 16038370Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Nafarelin (substance)
SNOMED CT
109046009
UMLS CUI
C0064906
RxNorm CUI
28656

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.